AVAI (Avai Bio) Sloan Ratio %: 0.00% (As of Dec. 2025)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.13
! 3 Warning Signs
View Full Analysis

What is Avai Bio Sloan Ratio %?

Avai Bio AVAI +5.80% 24 Sloan Ratio % is 0.00% as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Avai Bio's Sloan Ratio for the quarter that ended in Dec. 2025 was 0.00%.

As of Dec. 2025, Avai Bio has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Avai Bio  (OTCPK:AVAI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2025, Avai Bio has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Avai Bio Sloan Ratio % Related Terms


Avai Bio Sloan Ratio % Historical Data

* Premium members only.

The historical data trend for Avai Bio's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Sloan Ratio % Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Sloan Ratio %
Get a 7-Day Free Trial -36.76 82.20 -108.30 -204.04 0.00

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AVAI vs IPM, RCT, LPSN: Sloan Ratio % Comparison

For the Software - Application subindustry, Avai Bio's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avai Bio Sloan Ratio % vs Software Industry

For the Software industry and Technology sector, Avai Bio's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Avai Bio's Sloan Ratio % falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
Sloan Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Avai Bio's Sloan Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2025 )-Cash Flow from Operations (A: Mar. 2025 )
-Cash Flow from Investing (A: Mar. 2025 ))/Total Assets (A: Mar. 2025 )
=(-1.142--1.161
-0)/0.225
=8.44%

Avai Bio's Sloan Ratio for the quarter that ended in Dec. 2025 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2025 )
=(-1.031--1.147
-0)/0.173
=67.05%

Avai Bio's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was 0.464 (Mar. 2025 ) + -0.488 (Jun. 2025 ) + -0.453 (Sep. 2025 ) + -0.554 (Dec. 2025 ) = $-1.03 Mil.
Avai Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was -0.188 (Mar. 2025 ) + -0.24 (Jun. 2025 ) + -0.372 (Sep. 2025 ) + -0.347 (Dec. 2025 ) = $-1.15 Mil.
Avai Bio's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 0 (Mar. 2025 ) + 0 (Jun. 2025 ) + 0 (Sep. 2025 ) + 0 (Dec. 2025 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Sloan Ratio % →
What does a Sloan Ratio % of 0.00% mean?
Avai Bio (AVAI) has a Sloan Ratio % of 0.00% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Avai Bio and its competitors.
Is Avai Bio's Sloan Ratio % too high?
Avai Bio's current Sloan Ratio % is 0.00%. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Sloan Ratio % compare to IPM and RCT?
Avai Bio's Sloan Ratio % of 0.00% can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Software company?
A good Sloan Ratio % depends on the Software industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Avai Bio and its competitors. Avai Bio's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Avai Bio (AVAI), the current Sloan Ratio % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price